Myriad Genetic Laboratories (Salt Lake City, UT) is following the lead of Digene with direct-to-consumer marketing. The difference? Digene’s test is designed to detect a virus (human papilloma virus) that affects approximately 20 million people in the United States and can cause cervical cancer. Myriad’s BRACAnalysis test, which costs $3,125, has a much smaller candidate pool, and many are concerned that the advertising may lead to unnecessary testing.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

October 2007 - Table of Contents

LIR October 2007 (full PDF issue)

Labs Boost Efficiency With Lean and Six Sigma Techniques

Myriad Premieres TV Ad for Breast Cancer Test

LabCorp Nears Close on Indiana Laboratory

A Closer Look at a Provider of Direct Access Testing

Lab Industry Looks to Lean Manufacturing Experts to Boost Efficiency

As Lab Vendors Consolidate, Keep Your Eye on Siemens

United Healthcare to Pay Up to $20 Million to Resolve Claims Concerns

Lab Stocks Fall 2%; Bio-Reference Climbs

Midwest Lab Sees Steady Demand for CYP450 AmpliChip Testing